SA cancer research group ramping up Spain expansion

San Antonio has a deep bench and long history in cancer research, and it’s expanding on that expertise and infrastructure on multiple fronts, drawing more talent and investment to back that growth. This spring, San Antonio-based NEXT Oncology launched operations in Spain with an early-phase clinical trial in Madrid. It’s part of a growth plan founder Dr. Anthony Tolcher outlined …

NEXT Oncology Enrolls First Patient in Madrid Phase I Clinical Research Center

When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer (TNBC) with an anti-drug conjugate used in …

Quirónsalud launches two new phase I clinical trial units in Madrid and Barcelona

El Grupo Quirónsalud ha puesto en marcha dos nuevas unidades de ensayos clínicos de fase I gracias al acuerdo alcanzado con NEXT Oncology, empresa estadounidense líder en el desarrollo de este tipo de ensayos creará en Europa. The Quirónsalud Group has launched two new phase I clinical trial units thanks to the agreement reached with NEXT Oncology, a leading American company in the development of …

Next Oncology Expends Phase I Program with Virginia Cancer Specialists Partnership

For the latest installment of the Inside the Practice Segment of the Medical World News® broadcast, CancerNetwork® spoke with Anthony W. Tolcher, MD, co-founder of NEXT Oncology and a medical oncologist at Texas Oncology, as well as Alexander I. Spira, MD, PhD, director of Virginia Cancer Specialists Research Institute and the Phase I Trial Program, to discuss their new partnership and how …

Medical World News® Inside the Practice: CancerNetwork® With Anthony W. Tolcher, MD, and Alexander I. Spira, MD, PhD, on Expand Access to Phase 1 Cancer Trials

For the latest installment of the Inside the Practice Segment of the Medical World News® broadcast, CancerNetwork® spoke with Anthony W. Tolcher, MD, co-founder of NEXT Oncology and a mMedical oOncologist at Texas Oncology, as well as Alexander I. Spira, MD, PhD, Medical Oncologist and dDirector of Virginia Cancer Specialists Research Institute and the Phase I Trial Program, to discuss their new …

What Did We Learn From IMpower010 in Resectable NSCLC

What the New KRAS Inhibitor Means for Lung Cancer

Last month, the FDA granted accelerated approval of sotorasib (Lumakras) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following the results of the phase II CodeBreaK 100 trial, data from which were presented during the recent virtual American Society of Clinical Oncology annual meeting. In this second of four exclusive episodes, MedPage Today brought together three leaders in the field —  moderator Vinay Prasad, MD, …